This week in Drug Discovery (22 – 26 September)
News round-up for 22 – 26 September by Bruno Quinney, Content Team at DDW.
Research into Huntington’s disease has made global headlines this week, with clinical trial results at University College London (UCL) showing gene therapy could slow down the disease’s progression. Elsewhere, a big-name drug discovery partnership is set to develop AI projects and new synthetic kidneys could boost research into kidney disease.
The top stories:
Trial shows slowing of Huntington’s progression for the first time
A global clinical trial for a new Huntington’s disease gene therapy has posted positive results, including 75% less progression of the disease.
‘Revolutionary’ synthetic kidneys provide boost to kidney research
New research led by Californian institute USC Stem Cell has broken new ground by building mouse and human synthetic kidneys.
Dualitas Therapeutics to develop next-gen specific antibodies
Biotechnology company Dualitas Therapeutics has launched from stealth with a $65 million (£48 million) Series A financing round to develop next-generation bispecific antibodies (BsAbs).
Merck and Siemens extend partnership for AI projects
US pharmaceutical giant Merck and technology company Siemens have signed a new Memorandum of Understanding (MoU), extending their strategic partnership to accelerate AI and data-driven drug discovery and development.
Prota awarded for research on peanut oral immunotherapy
Biopharmaceutical company Prota Therapeutics has announced its research, in partnership with Murdoch Children’s Research Institute (MCRI), has been awarded a prize at the European Academy of Allergy and Clinical Immunology (EAACI) for outstanding oral abstract presentation.
